Author

M. Mattos

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6 Immunology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 9 Organism:human· 8 Research Focus:drug response / drug discovery· 6 Organism:mouse· 5 Assay:proteomics· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:differential expression· 2

Frequent Co-Authors

T. M. L. Souza· 8 shared C. Q. Sacramento· 7 shared N. Fintelman-Rodrigues· 7 shared P. T. Bozza· 7 shared A. C. Ferreira· 6 shared J. R. Temerozo· 6 shared C. S. de Freitas· 5 shared F. A. Bozza· 5 shared

Activity by Year

2017-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersMicrobiology

T. M. L. Souza

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Macrophages undergo necroptosis during severe influenza A infection and contribute to virus-associated cytokine storm

A. C. Ferreira, C. Q. Sacramento, F. S. Pereira-Dutra, N. Fintelman-Rodrigues, P. P. Silva, M. Mattos, C. S. de Freitas, A. Marttorelli, G. R. de Melo, M. C. Macedo, I. G. Azevedo-Quintanilha, A. S. Carlos, J. V. Emidio, C. C. Garcia, P. T. Bozza, , T. M. L. Souza

This study shows that IAV or HA induces necroptosis in macrophages, contributing to cytokine storm and lung injury, and that anti-TNF treatment prevents these effects.

bioRxiv · Apr 20, 2022 · PreprintImmunology

Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo

O. A. Chaves, C. Q. Sacramento, A. C. Ferreira, M. Mattos, N. Fintelman-Rodrigues, J. R. Temerozo, D. P. Pinto, G. P. E. da Silveira, L. B. da Fonseca, H. M. Pereira, A. S. Carlos, J. d. C. P. d'Avila, J. P. B. Viola, R. Q. Monteiro, L. Vazquez, , T. M. L. Souza

This study shows that atazanavir inhibits SARS-CoV-2 Mpro, effectively reducing replication of both B.1 and gamma variants in vitro and in vivo.

bioRxiv · Nov 24, 2021Pharmacology & Toxicology

Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.

C. Q. Sacramento, N. Fintelman-Rodrigues, S. S. G. Dias, J. R. Temerozo, A. d. P. D. Da Silva, C. S. da Silva, A. C. Ferreira, M. Mattos, V. C. Soares, F. Pereira-Dutra, M. D. Miranda, D. F. Barreto-Vieira, M. A. N. da Silva, S. de Siqueira Santos, M. Torres, , T. M. L. Souza

This paper shows mefloquine inhibits SARS-CoV-2 infection in relevant cells more effectively than chloroquine without promoting viral mutations.

bioRxiv · Jul 21, 2021Microbiology

Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

N. Fintelman-Rodrigues, C. Q. Sacramento, C. Ribeiro Lima, F. Souza da Silva, A. Ferreira, M. Mattos, C. S. de Freitas, V. Cardoso Soares, S. da Silva Gomes Dias, J. R. Temerozo, M. Miranda, A. R. Matos, F. A. Bozza, N. Carels, C. Roberto Alves, , T. M. L. Souza

This study shows that atazanavir inhibits SARS-CoV-2 replication and reduces pro-inflammatory cytokine production in vitro.

Antimicrobial Agents and Chemotherapy · Sep 21, 2020Peer-reviewedMicrobiology

Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators

S. S. Gomes Dias, V. S. Cardoso, A. C. Ferreira, C. Q. Sacramento, N. Fintelman-Rodrigues, J. R. Temerozo, L. Teixeira, E. A. Barreto, M. Mattos, C. S. de Freitas, I. Azevedo-Quintanilha, P. P. A. Manso, E. D. Hottz, C. R. R. Pao, D. C. Bou-Habib, , P. T. Bozza

This study shows that lipid droplets support SARS-CoV-2 replication and inflammatory mediator production, with DGAT-1 inhibition reducing viral replication and inflammation.

bioRxiv · Aug 22, 2020 · PreprintImmunology

VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells.

J. R. Temerozo, C. Q. Sacramento, N. Fintelman-Rodrigues, C. R. R. Pao, C. S. de Freitas, S. d. S. G. Dias, A. C. Ferreira, M. Mattos, V. C. Soares, L. Teixeira, I. G. de Azevedo-Quintanilha, E. D. Hottz, P. Kurtz, F. A. Bozza, P. T. Bozza, , D. C. Bou-Habib

The paper shows elevated VIP plasma levels in severe COVID-19 patients correlate with survival and protective effects against SARS-CoV-2 in vitro.

bioRxiv · Jul 25, 2020Immunology

The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2

C. Q. Sacramento, N. Fintelman-Rodrigues, J. R. Temerozo, A. d. P. D. Da Silva, S. da Silva Gomes Dias, A. C. Ferreira, C. d. S. da Silva, M. Mattos, C. R. R. Pao, C. S. de Freitas, V. Cardoso Soares, L. V. B. Hoelz, T. V. A. Fernandes, F. S. C. Branco, M. M. Bastos, , T. M. L. Souza

This study evaluates the antiviral activity of daclatasvir and sofosbuvir against SARS-CoV-2 in vitro, showing inhibition of viral replication and associated pathologies.

bioRxiv · Jun 15, 2020 · PreprintMicrobiology

Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication

A. Ferreira, P. Reis, C. de Freitas, C. Queiroz, L. Villas Boas Hoelz, M. Bastos, M. Mattos, E. Correia Loiola, P. Trindade, Y. Rangel Vieira, G. Barbosa-Lima, H. de Castro Faria Neto, N. Boechat, S. Rehen, K. Bruning, , T. Souza

This study shows sofosbuvir inhibits chikungunya virus replication in cell cultures and animal models, with selectivity over ribavirin and efficacy in vivo.

bioRxiv · Jul 2, 2018Microbiology

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo

C. de Freitas, L. Higa, C. Sacramento, A. Ferreira, P. Reis, R. Delvecchio, F. Monteiro, G. Barbosa-Lima, Y. Vieira, M. Mattos, L. Hoelz, R. Leme, M. Bastos, F. Bozza, P. Bozza, , T. Souza

This study shows that sofosbuvir inhibits Yellow fever virus replication in vitro and protects mice from infection, suggesting it as a potential therapeutic option.

bioRxiv · Feb 15, 2018Microbiology

Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequela

A. Ferreira, C. Valle, P. Reis, G. Barbosa-Lima, Y. Vieira, M. Mattos, P. Silva, C. Sacramento, H. Neto, L. Campanati, A. Tanuri, K. Bruning, F. Bozza, P. Bozza, T. M. L. Souza

This study shows sofosbuvir reduces ZIKV levels and improves survival and long-term memory in infected mice.

bioRxiv · Apr 20, 2017Microbiology